Erectile dysfunction affects 31 -52% of American men. Although considerable advances have been made in the diagnosis and treatment of erectile dysfunction in the past decade, more than 80% of men with erectile dysfunction are not treated because they do not seek medical attention or their physicians do not initiate a dialogue about sexual problems during their visits. This despite patients' desires to confront sexual problems and receive treatment. Most subgroups of men can now be effectively treated for sexual dysfunction. Although men with severe cardiac disease may require stabilization of their cardiac condition before treatment, most can successfully return to an active sex life. Some men, however, do not respond to the use of oral agents. These men can be treated with second-and third-line treatment modalities or with the newer concept of combinedmodality treatment. Despite excellent treatment alternatives, many men have low libido or hypoactive sexual desire disorder. In the ultimate resolution of a patient's sexual dysfunction, physicians must open a free and sympathetic dialogue and offer a full spectrum of treatment modalities tailored to the individual patient and partner. If initial treatment modalities fail, more invasive alternatives or combination therapy should be offered to cure the patient's erectile dysfunction.
Introduction
Since the introduction of sildenafil in 1998, there has been a revolution in the treatment of erectile dysfunction (ED) throughout the world. The scientific and marketing efforts of physicians and the pharmaceutical industry have increased the presentation rates of ED by 250% in the USA, 55% in Germany, 103% in the UK, 279% in Mexico, and 90% in Spain compared with the presentation rates before sildenafil was available. 1 Similarly, the number of prescriptions for drugs for the treatment of ED before the introduction of sildenafil was slightly more than 4 million, with most men with ED being treated with intracavernosal alprostadil. Shortly after the introduction of sildenafil in the USA, the number of sildenafil prescriptions for the treatment of ED increased 438% to more than 19 million between April 1998 and December 1999. 1 This increase was led by physicians and media who educated the public on the importance of ED and the ability to treat ED effectively.
A number of studies have demonstrated the improvement in quality of life for patients undergoing ED treatment. In 1999, Parkerson et al 2 studied 1073 men in the USA and Europe with ED treated with intracavernosal alprostadil. These patients were followed up for 19 months, and there was a demonstrated improvement in mental status in all groups, despite a decrease in physical status associated with increasing age. Interestingly, social status also increased in Europe, although not in the USA. In 1999, Litwin and colleagues 3 reviewed the quality of life of 438 men undergoing treatment for carcinoma of the prostate with X-ray therapy or radical prostatectomy. These patients include those undergoing not only nerve-sparing but also nonnerve-sparing radical prostatectomy. An evaluation was performed using the UCLA prostate cancer index. Sexual function during follow-up increased in the first year for all groups and decreased slightly for radiation therapy patients in the second year. Sexual function, however, improved in all patients, but response was related to age, prediagnosis ED, and non-nerve-sparing radical prostatectomy. It has been estimated that 1 in 10 men worldwide have ED and that it is the most common chronic medical disorder in men older than 40 y. 1 Predictors of ED according to the National Health and Sexual Life Survey include perceived health, emotional stress, and both current and prepuberal sexual coercion. 4 The Massachusetts Male Aging Study recorded depression, unhappiness with life, and pessimistic attitude as significant risk factor predictors for ED. 5 Despite these revelations in the understanding and treatment of ED, there are many men who have sought help for ED only to encounter physicians who are uneasy and resistant to the investigation and treatment of ED. Part of the problem includes the issue of men's health. It is estimated that in the USA men have more than 150 million fewer physician visits then women, even excluding perinatal visits. This partially accounts for not only the reluctance in treating ED, but also the lower life expectancy for men compared with women. Marwick 6 surveyed patients' expectations and experiences in discussion of sexual issues with their physicians. A total of 71% of patients stated that they believed that physicians would not recognize ED as a medical problem, whereas 68% of patients feared that discussing sexuality with their physicians would embarrass their physicians.
Patients also require education and experience in the use of ED agents for optimal success. Indeed, with sildenafil, as many as six to eight attempts at treatment with sildenafil may be required to optimize responses. 7 First attempts, irrespective of severity of ED, are successful in slightly more than 50% of first-time uses compared with almost 80% at six attempts or more. Although patients with severe ED have a lower expectation of ultimate success, the increase in success with further attempts mirrors that of both mild-to-moderate ED and the ED population at large (Figure 1 ).
Patients and their partners must be educated in lifestyle issues that preserve erectile function and, indeed, optimize the response to agents for the treatment of ED. Smoking is one of the most important issues of lifestyle that can affect erectile function. The Massachusetts Male Aging Study in its follow-up publication reported an increase in ED with smoking in addition to other risk factors, such as diabetes, heart disease and hypertension. 8 Indeed, the incidence of ED increased among smokers with some stability in onset if men stopped smoking. The Health Professions Follow-Up Study 9 of 32 287 patients demonstrated a relative risk of ED of 2.2 (95% confidence interval, 1.9 -2.5) in men who smoked. Indeed, the effects of smoking in the laboratory and in clinical research have been widely published. Smoking appears to enhance prostacyclin production, increase platelet vessel wall interaction, and reduce endothelium-mediated forearm vessel dilation in long-term smokers. 10 Smoking has also been demonstrated to decrease endothelial nitric oxide synthase activity and impair the release of nitric oxide. Finally, there has been a demonstrated increase in superoxide ion-mediated endothelium-derived relaxing factor degradation in smokers. It is important, therefore, to educate patients that ED can be treated in more than 80% of men with expectations of excellent outcomes and success with low morbidity and normal risks. 10 Patients should also be educated and instructed that lifestyle counseling may assist their longevity and health and improve not only erectile function but also response to ED treatment. These counseling points should include smoking cessation, moderate alcohol intake, reduction in fat and cholesterol, exercise, improvement and compliance with cardiovascular and diabetic medications, stress reduction, depression treatment, and an optimism of ED treatment outcomes and resolution with appropriate management.
Whom can we treat?
It is clear that the outcome of oral treatment for ED is successful in most patients with both mild-tomoderate and severe ED. Although the responses in populations at large are somewhat less than those of clinical study groups, it still remains clear that most patients with organic, psychogenic, or mixed ED can be effectively treated. Indeed sildenafil, the only carefully studied oral agent with long-term experience, demonstrates a 69% response to organic ED and more than 80% for both psychogenic and mixed ED. 11 Jarow et al 11 have examined the various causes of ED, comparing baseline with sildenafil treatment. Sildenafil has been demonstrated to improve ED across causes. If one separates patients by severity, patients with severe ED respond to sildenafil with improved erections in 65% of patients, compared with 87% of patients with mild-to-moderate ED. Older patients do not respond as well but continue to respond satisfactorily. Patients 65 y or older have a 69% improvement compared with 78% in those patients younger than 65 y. 11 The most difficult patients to treat are those patients with additional complications associated with ED and systemic disease. Indeed, as a group, those patients who have undergone radical prostatectomies respond only 43% of the time to sildenafil compared with 25% of those taking placebo. 11 If one stratifies these patients by nerve-sparing radical prostatectomy, however, one sees a marked improvement in response in those patients undergoing bilateral nerve-sparing radical prostatectomy. Zippe et al 12 reported that 71.7% of patients who had undergone bilateral nerve-sparing prostatectomy had erections capable of vaginal penetration compared with 50% of those undergoing unilateral nerve-sparing radical prostatectomy and only 15.4% of patients undergoing non-nerve-sparing radical prostatectomy. Indeed, partner satisfaction mirrors these results, with 66% of partners of bilateral nerve-sparing prostatectomy patients, 41.6% of partners of unilateral nerve-sparing prostatectomy patients, and 15.4% of partners of non-nerve-sparing radical prostatectomy patients suggesting satisfaction. 13 Patients with diabetes are likewise difficult to treat. Indeed, ED patients with both type 1 and type 2 diabetes can be satisfactorily treated. Treatment is difficult, however, because of complications from diabetes. Those patients with more than two complications have only a 43% probability of improved erections compared with 69% of patients with diabetes and no diabetic complications. 13 Thus, sildenafil can be useful in the treatment of most patients with ED. In that group of 20 -40% of patients who do not respond to sildenafil, rescue treatments can be carried out. Indeed, Phelps et al 14 
Further investigation continues to focus on combination therapy. Indeed, in the future combination therapy may prove promising for many of our patients with ED who are not responsive to single oral agents. Mydlo et al 16 reviewed a combination therapy of Medicated Urethral System for Erection (MUSE) and sildenafil. A total of 65 of 214 men treated for ED were not satisfied with maximum doses of sildenafil or MUSE. A total of 60 of 65 patients achieved good satisfaction rates by combining the two agents. Responses to the Global Assessment Question were significantly improved (P < 0.05) with combination therapy. The Global Assessment Question measured 23 patients undergoing combination therapy compared with 19.2 patients using sildenafil alone and 15.2 using MUSE alone. This combination appears to help significant numbers of patients who do not respond to individual treatment alternatives. Benevides and Carson 17 used a combination of penile prosthesis and MUSE in those patients with penile prosthesis who experienced mechanical failure or cold glans penis after penile prosthesis. Seven of 11 patients in whom penile prosthesis failed were restored for coital function with MUSE, and 10 of 17 patients with cold glans penis experienced improvement with use of MUSE and their penile prosthesis. In 1998, Soderdahl et al 18 reported a combination of penile prosthesis and vacuum erection device. They reported that 11 -12 men responded satisfactorily to the combination with improved glans rigidity and improved coital satisfaction using vacuum erection devices and inflatable penile prostheses. Clearly, the caveat to this combination is potential damage of aggressive vacuum erection device on penile prosthesis cylinders. Careful use, however, appears to be a reasonable alternative.
Some patients are clearly difficult to treat and outcomes of treatment are often unsatisfactory. These patients include both those in whom all pharmacologic agents have failed and penile prostheses have resulted in significant morbidity. Similarly, it is difficult to provide satisfactory sexual activity to patients with low libido, despite improvement of erectile function. A typical difficult clinical problem is that of corporal fibrosis with ED. Patients may have corporal fibrosis as a result of multiple penile prosthesis implantations, perioperative device infection, Peyronie's disease, preimplant priapism, or the use of prolonged injection therapy. We reviewed 220 men with penile prosthesis implantation from 1993 to 2001, 32 of whom had significant corpus cavernosum fibrosis (C Carson, data on file). Chart review and telephone interview 9 -96 months following surgery demonstrated 32 of 32 patients with mechanically functional penile prostheses. Four patients were excluded because of inability to place penile prothesis or explant for infection without subsequent prosthesis implantation. Origins of ED and corpora fibrosis included postpenile prosthesis infection in 24, priapism in four, and postinjection therapy fibrosis in four patients. The survey conducted demonstrated erection satisfactory for coitus in 26 (81.3%) of 32 and coital satisfaction in 23 (71.9%) of 32. The results for three patients (9.4%) are pending further surgery. Reasons for dissatisfaction included penile size (length) in 18 (56.3%) of 42, decreased penile sensation in two (6.2%) of 32, and other concerns in nine (28.1%) of 32. Thus, although the surgical placement of penile prosthesis in these patients with corpora fibrosis is possible and may be successful mechanically, coital satisfaction is substantially less than that of patients undergoing penile prosthesis without significant corpus cavernosum fibrosis.
Patients with severe cardiac disease are also difficult to treat. The Princeton guidelines published in 2000 suggest that patients at low risk for complications (less than three major risk factors for coronary artery disease or uncomplicated past myocardial infarction) can be safely treated and resume sexual activity. 19 Those patients with intermittent risks (three or more major risk factors for coronary artery disease or recent myocardial infarction) should have further cardiologic evaluation with stratification into low-or high-risk ranges and should be delayed in resumption of aggressive sexual activity. High-risk patients, including those with unstable angina, myocardial infarction less than 2 weeks previously, stroke, and uncontrolled hypertension, should be stabilized with specific treatment, whether cardiac or vascular, before resuming sexual activity or before undergoing treatment for ED. Thus, patients with high-risk cardiac disease are best advised to delay treatment until their cardiac status has been stabilized and improved. Treatment in cooperation with a cardiologist is essential in these complex and difficult-totreat men.
One of the most difficult groups of men to treat, and men who respond poorly, are those with diminished libido. Currently, this group of patients is classified as having hypoactive sexual desire disorder (HSDD) and is difficult to treat despite adequate treatment and restoration of erectile function. Indeed, a recent review by Rosen 20 suggested that more than one third of men in an ED clinic have HSDD. The causes for HSDD that are treatable are few. Some patients with low testosterone levels may exhibit decreased libido and can be successfully treated with testosterone or androgen replacement. Similarly, pharmacologic agents, such as spironolactone, reserpine, and selective serotonin reuptake inhibitors, may decrease libido, and modification of these agents may improve sexual desire. The usual manifestations of HSDD include loss of interest in sex, avoidance of sexual situations, decreased frequency and initiation of sexual encounters, decrease in sexual thoughts and fantasies, and diminished masturbation. Indeed, chronic illnesses can be associated with low sexual desire.
Zorzon et al 21 reported a low libido (HSDD) in 39.5% of men with multiple sclerosis of which 63.2% had ED. Fowler et al 22 reported satisfactory treatment of multiple sclerosis-associated ED with sildenafil; however, the impact of chronic disease on sexual desire may preclude the satisfactory treatment of many of these individuals. Sexual desire with chronic renal failure was reported by Salvatierra et al, 23 with some resolution and improvement in sexual desire following renal transplantation. However, Malavaud et al 24 reported that, despite transplantation, patients experienced lower coital satisfaction, erectile function and sexual desire than age-matched controls. Testosterone, however, is not the entire answer to hypoactive sexual desire. Indeed, Nasong and Punwaney 25 investigated 180 men with the Boston Sexual Function Inventory. They found that low testosterone levels and low sexual drive have a positive predictive value of 59.2%, a negative predictive value of 55.9%, and a total yield of 26.9%. They found that mean total and free testosterone levels were in the normal range for many men with low sexual desire. Morales and Heaton, 26 using the Sexual Desire Domain of the International Index of Erectile Function, identified that in 2.2% of 138 men with ED and severe hyperprolactinemia (prolactin, > 35 ng=ml) there was no apparent correlation between prolactin level and sexual desire, despite a highly correlated ED domain, with most patients exhibiting severe ED.
Many as yet to be defined factors may play a role in low sexual desire. Reiter et al 27 investigated dehydroepiandrosterone (DHEA) concentrations and ED. They followed up 40 men with ED and a DHEA level less than 1.5 ng=ml treated with 50 mg of DHEA or placebo. The patients' mean age was 56.5 y, and all had had ED for more than 6 months. Other hormone levels were normal and patients had no other significant organic causes for ED. The authors demonstrated an improvement in ED with DHEA treatment after 24 weeks and, interestingly, a highly statistically significant improvement in sexual desire during the same 24 weeks (P < 0.001).
Conclusion
Education of ED patients and partners is critical for serving our patients with ED and improving their lives. It is important to educate physicians to discuss ED with patients. Physicians must 'ask the question.' By initiating the conversation, physicians will often break down communication barriers and allow patients to discuss their sexuality and ED. Although this aspect of a patient's health may not seem to be critically important, it may be a harbinger of more significant underlying organic disease processes and may have a substantial impact on patient, partner, and the couple. It may, indeed, be a marker for the patient's quality of life in a larger sense. Patients need to be informed that treatment is available for ED. Physicians need to be comfortable in speaking with their patients about ED and counseling them about the importance of ED in their lives. 28 Currently, more than 80% of men will respond to oral medications such as sildenafil. In those patients in whom responses are inadequate, second-line, third-line and combination therapy may help. Similarly, trials of more than a single dose of oral medications are critical in establishing the optimal response to oral treatment. Despite these best efforts, however, some patients cannot be treated easily. These include patients with significant comorbid conditions, especially severe cardiac disease. Likewise, patients with severe corpus cavernosum fibrosis may respond poorly to pharmacologic agents of any sort and, indeed, may be difficult to treat surgically. Because many of these patients do respond to functional penile prostheses and coital satisfaction, treatment with surgical intervention and penile prosthesis implantation after careful patient counseling may be appropriate. Combination therapy with different medications, devices and medications, and combinations of devices may also adequately treat some of these individuals.
Perhaps the most difficult patients to treat are those with HSDD or low libido. These patients, despite adequate response to medications with restoration of erectile function, may have little or no interest in pursuing sexuality. Careful counseling of these patients, investigation of their hormone status, and treatment of underlying chronic disease conditions may restore libido in some of these individuals. Careful history taking and identification of medications and psychological or physical conditions that hamper sexual desire are essential to effective treatment. This group of patients remains one of the most challenging groups to deal with in our patient populations.
